Skip to main content
. 2011 Aug;72(2):306–320. doi: 10.1111/j.1365-2125.2011.03962.x

Table 2.

Structural parameter estimates for the models

Population mean, θ (%RSE)
Omalizumab or IgE parameter* Control, constant Exponential Feedback interim Feedback final
Clearance omalizumab, CLX/F (l day−1) 0.214 0.207 (2.4) 0.207 (2.3) 0.206 (2.1)
Clearance IgE, CLE/F (l day−1) 3.21 2.83 (3.5) 2.83 (3.6) 2.87 (4.3)
Clearance complex, CLC/F (l day−1) 0.717 0.538 (3.5) 0.533 (3.4) 0.535 (4.3)
Volume omalizumab and IgE, VX/F and VE/F (l) 9.41 8.61 (1.5) 8.61 (1.5) 8.62 (1.4)
Volume complex, VC/F) (l) 7.15 (1.8)**
Absorption rate, ka (day−1) 0.446 (3.2)**
Binding dissociation constant, Kd (nm) 1.93 2.11 (4.5) 2.10 (4.4) 2.15 (4.7)
Kd change with total omalizumab to total IgE ratio, α 0.0945 0.0635 (19) 0.0659 (18) 0.0532 (24)
IgE production prior to omalizumab, RB (µg day−1) 982 966 (3.6) 965 (3.6) 967 (4.4)
IgE production at new equilibrium, RN (µg day−1) 188 (31) 168 (17) 253 (13)
Rate of change in IgE production with omalizumab, kM (% year−1) 53.9 (12) 58.5 (5.1) 53.8 (8.4)
Background (placebo) rate of change in IgE production, kE (% year−1) 0.197 ± 1.47***

These analyses used data from studies in Table 1 except study Q0673g. Note that minimization for the control (constant) model terminated with errors and should be regarded cautiously. RSE, relative standard errors; these are missing from the control model as it terminated with rounding errors and did not run the $COV procedure.

*

Depending on covariate adjustment for each parameter, values are given for a 70 kg, 20 kgm−2 BMI, Caucasian male aged >12 years with baseline IgE value of 365 ng ml−1.

**

Values for VC and ka were fixed from a separate first order conditional with interaction estimation using data from single-dose bioequivalence studies.

***

The background rate of change in IgE production was estimated independently from the placebo data and was fixed in the estimation process; the standard error is shown on the original scale.